Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases (Q40380082)

20 September 2017

Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases (English)

1 reference

20 September 2017

1 reference

Whang PG

1

1 reference

20 September 2017

Gamradt SC

series ordinal

2

1 reference

20 September 2017

Gates JJ

series ordinal

3

1 reference

20 September 2017

Lieberman JR

series ordinal

4

1 reference

20 September 2017

1 January 2005

1 reference

Prostate Cancer and Prostatic Diseases

20 September 2017

1 reference

20 September 2017

8

1 reference

20 September 2017

4

1 reference

20 September 2017

327-334

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500823

20 September 2017

0 references

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Mechanisms underlying ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

New insights into proteasome function: from archaebacteria to drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

How proteolysis drives the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Roles of ubiquitin-mediated proteolysis in cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The ubiquitin-proteasome pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

An essential role for NF-kappaB in preventing TNF-alpha-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Suppression of TNF-alpha-induced apoptosis by NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

The proteasome is involved in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500823

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500823

1 reference

Dimensions Publication ID

20 September 2017

0 references

1 reference